long-term follow-up from a phase ii trial of olutasidenib in idh1-mutated aml
Published 2 days ago • 24 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
1:47
limber-treg108: ck0804 add-on therapy in patients with mf with suboptimal response to ruxolitinib
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
1:51
treatment schedule for ruxolitinib in patients with mpns and how to assess response
-
15:41
bladder problems - rife frequencies treatment - energy & quantum medicine with bioresonance
-
2:41
israeli company on the edge of finding diabetes cure
-
21:38
drawing the line: the rationale behind blood tube collection order
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:43
extended follow-up of the alpine trial: superior outcomes with zanubrutinib in r/r cll/sll
-
2:09
advancing cml treatment: novel drugs, personalized treatment strategies, and improving tfr
-
2:41
bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
-
8:03
phase ii trial of navitoclax and ruxolitinib in high-risk r/r myelofibrosis
-
3:35
a trial investigating the addition of blinatumomab to consolidation chemotherapy in ph- all
-
1:57
impact of age on treatment outcomes in b-cell all
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:53
parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib
-
1:33
an update on the phase i/ii ruby trial of reni-cel gene therapy in patients with severe scd
-
1:44
updates from the phase ii animate trial of nivolumab in r/r chl
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study